Who makes gilteritinib mini tablet?

gilteritinib mini tablet is developed by Astellas Pharma Global Development, Inc..

What development phase is gilteritinib mini tablet in?

gilteritinib mini tablet is in Phase 1.

Last reviewed 2026-04-19 · How we verify

gilteritinib mini tablet

Astellas Pharma Global Development, Inc. · Phase 1 active Small molecule

At a glance

Generic name	gilteritinib mini tablet
Also known as	ASP2215
Sponsor	Astellas Pharma Global Development, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

gilteritinib mini tablet CI brief — competitive landscape report
gilteritinib mini tablet updates RSS · CI watch RSS
Astellas Pharma Global Development, Inc. portfolio CI